Drugs / TD-0714
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02709928 | Mar → Nov 2016 | — | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT02639078 | Nov 2015 → Feb 2016 | — | Theravance Biopharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-10-25 | Theravance Biopharma | Results Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP) theravance.com ↗
Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today announced positive results, including biomarker data, from its Phase 1 multiple-ascending dose (MAD) clinical trial of TD-0714, the lead molecule in the Company's neprilysin (NEP) inhibitor program for the treatment of a range of major cardiovascular and renal diseases. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-10-25 | Theravance Biopharma | Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP) theravance.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TD-0714 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02709928 ↗ |